Overview

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

Status:
Completed
Trial end date:
2019-02-04
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.
Phase:
Phase 3
Details
Lead Sponsor:
Urovant Sciences GmbH
Treatments:
Tolterodine Tartrate